Corixa [CRXA] - cancer vaccines Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corixa [CRXA] - cancer vaccines

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andreas Helke who started this subject	12/3/2002 3:31:55 AM
From: sim1	Read Replies (1) of 222

FDA plan for Bexxar raises Corixa shares BLOOMBERG NEWS Corixa Corp. shares rose as much as 31 percent yesterday after the company said the Food and Drug Administration will consider its Bexxar cancer treatment again. Shares in the Seattle biotech company rose as high as $9 in after-market trading after falling 37 cents to $6.88 in yesterday's trading on the Nasdaq. After the FDA rejected Bexxar in March, Corixa and drug partner GlaxoSmithKline Plc were scheduled to appear before a panel of agency advisers to appeal that decision. The companies said yesterday that they sent the agency new Bexxar data in October, which persuaded officials to reconsider the drug application. "The agency felt they had sufficient information to bring us to the (expert panel) to discuss approval, which is different than going to the panel with a dispute," Corixa Chief Financial Officer Michelle Burris said. The FDA plans to reach a decision on the product by May 2, under an accelerated six-month review, Burris said. The drug is designed to treat lymphoma by linking a radioactive particle to an antibody that targets cancer cells.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next